---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-006961"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T13:00:14.834469+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics receives Sandoz Paragraph IV notice challenging six RYZUMVI patents

## Summary
- Sandoz filed ANDA for generic RYZUMVI; alleges six Orange Book patents invalid/unenforceable/non-infringed.
- Challenged patents: 9,795,560, 10,278,918, 10,772,829, 11,090,261, 11,844,858, and 11,400,077.
- Two other RYZUMVI Orange Book patents (12,201,615 and 12,201,616) not challenged by Sandoz.
- Opus or its commercial partner may file patent infringement lawsuit to defend IP rights.

## SEC filing metadata
- accession: 0001140361-25-006961
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125006961/0001140361-25-006961-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125006961/ef20044862_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-006961
- JSON: https://secwatch.observer/filing/0001140361-25-006961.json
- Plain text: https://secwatch.observer/filing/0001140361-25-006961.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.